"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04097652","Mesenchymal Stem Cells for The Treatment of Acute Ischemic Stroke",,"Recruiting","No Results Available","Acute Ischemic Stroke","Biological: UMC119-06","The incidence and frequency of adverse events related to administration of UMC119-06.|Changes in Modified Rankin Score (mRS)|Changes in National Institute of Health Stroke Scale (NIHSS)|Changes in Barthel Index (BI)|Changes in Brain MRI","Meridigen Biotech Co., Ltd.","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 1","9","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMC119-06-01","December 5, 2019","December 2022","December 2023","September 20, 2019",,"April 23, 2021","Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare., New Taipei City, Taiwan",,"https://ClinicalTrials.gov/show/NCT04097652"
2,"NCT04914403","Mesenchymal Stem Cells for The Treatment of Frailty Syndrome",,"Recruiting","No Results Available","Frailty Syndrome","Biological: UMC119-06-05","The incidence and frequency of adverse events related to administration of UMC119-06-05.|Changes in exercise performance using 6-min walk test (6MWT).|Changes in grip strength.|Changes in quality of life measured by change in SF12 (12-Item Short Form).|Changes in physical activity using International Physical Activity Questionnaire (IPAQ) questionnaire|Changes in Forced Expiratory Volume in One Second (FEV1).|Changes in Clinical Frailty Scale.","Meridigen Biotech Co., Ltd.","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMC119-06-05-FS-01","September 1, 2021","December 2022","July 2023","June 4, 2021",,"April 7, 2022","Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare., New Taipei City, Taiwan",,"https://ClinicalTrials.gov/show/NCT04914403"
3,"NCT04206007","Mesenchymal Stem Cells for The Treatment of Chronic Obstructive Pulmonary Disease",,"Recruiting","No Results Available","Chronic Obstructive Pulmonary Disease Moderate","Biological: UMC119-06","The incidence and frequency of adverse events related to administration of UMC119-06.|Changes in Forced Vital Capacity (FVC).|Changes in Forced Expiratory Volume in One Second (FEV1).|Changes in the ratio of Forced Expiratory Volume in One Second to the Forced Vital Capacity (FEV1/FVC).|Changes in exercise performance using 6-min walk test (6MWT).|Changes in Quality Of Life using St. George's Respiratory Questionnaire Safety (SGRQ).|Changes in modified medical research council (mMRC) -dyspnea scale.","Meridigen Biotech Co., Ltd.","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 1","9","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMC119-06-COPD-01","June 11, 2020","March 31, 2022","December 31, 2023","December 20, 2019",,"April 23, 2021","Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare., New Taipei City, Taiwan",,"https://ClinicalTrials.gov/show/NCT04206007"
4,"NCT04347967","Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS)",,"Not yet recruiting","No Results Available","Acute Respiratory Distress Syndrome","Biological: UMC119-06","The incidence and frequency of adverse events related to administration of UMC119-06.|Changes in mortality status|Ventilator Free Days (VFD)|Change in Oxygenation Index (OI)|Change in Lung Injury Score (LIS)|Change in positive end-expiratory pressure (PEEP)|Change in Lung Static Compliance|Change in acute physiology and chronic health evaluation score (APACHE II)","Meridigen Biotech Co., Ltd.","All","20 Years to 85 Years   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMC119-06-ARDS-01","September 2021","December 2022","December 2023","April 15, 2020",,"May 18, 2021","Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare., New Taipei City, Taiwan",,"https://ClinicalTrials.gov/show/NCT04347967"
5,"NCT04893174","Mesenchymal Stem Cells for The Treatment of Knee Osteoarthritis (KOA).",,"Not yet recruiting","No Results Available","Osteoarthritis, Knee","Biological: UMC119-06-05|Device: Hyaluronic acid","The incidence and frequency of adverse events related to administration of UMC119-06-05.|Changes of total score in the Western Ontario and McMaster (WOMAC) assessment on the target knee.|Changes of arthritis pain on target knee using the 100-mm visual-analogue scale (VAS).|Whole Organ Magnetic Resonance Imaging Score (WORMS).|Changes in Kellgren-Lawrence (K-L) grading and joint space on target knee.|Amount of rescue medications required.","Meridigen Biotech Co., Ltd.","All","40 Years to 90 Years   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMC119-06-05-KOA-01","January 2022","September 2022","June 2023","May 19, 2021",,"May 28, 2021","Taipei Medical University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04893174"
